TD Asset Management Inc Raises Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

TD Asset Management Inc increased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) by 5.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 173,679 shares of the company’s stock after buying an additional 9,000 shares during the quarter. TD Asset Management Inc owned about 0.12% of Allogene Therapeutics worth $1,092,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ALLO. Rockefeller Capital Management L.P. grew its stake in shares of Allogene Therapeutics by 9.7% during the third quarter. Rockefeller Capital Management L.P. now owns 14,083 shares of the company’s stock valued at $151,000 after acquiring an additional 1,248 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Allogene Therapeutics by 6.2% during the fourth quarter. ProShare Advisors LLC now owns 22,181 shares of the company’s stock valued at $140,000 after acquiring an additional 1,297 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Allogene Therapeutics by 4.1% during the third quarter. MetLife Investment Management LLC now owns 42,018 shares of the company’s stock valued at $454,000 after acquiring an additional 1,668 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in shares of Allogene Therapeutics by 11.3% during the third quarter. Ensign Peak Advisors Inc now owns 20,910 shares of the company’s stock valued at $226,000 after acquiring an additional 2,120 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Allogene Therapeutics by 25.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,514 shares of the company’s stock valued at $91,000 after acquiring an additional 2,928 shares in the last quarter. 72.94% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Oppenheimer lowered their target price on Allogene Therapeutics from $32.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, March 1st. JMP Securities reduced their price objective on Allogene Therapeutics from $19.00 to $15.00 in a research report on Friday, May 5th. William Blair reiterated an “outperform” rating on shares of Allogene Therapeutics in a research report on Wednesday, March 22nd. The Goldman Sachs Group reduced their price objective on Allogene Therapeutics from $35.00 to $31.00 and set a “buy” rating for the company in a research report on Wednesday, March 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $23.00 price objective on shares of Allogene Therapeutics in a research report on Thursday, April 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Allogene Therapeutics Trading Up 2.1 %

NASDAQ ALLO opened at $6.36 on Thursday. Allogene Therapeutics, Inc. has a 1-year low of $4.42 and a 1-year high of $17.49. The company has a market capitalization of $927.54 million, a PE ratio of -2.61 and a beta of 0.77. The firm’s fifty day simple moving average is $5.39 and its 200-day simple moving average is $7.05.

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last posted its quarterly earnings results on Wednesday, May 3rd. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.05). Allogene Therapeutics had a negative return on equity of 50.21% and a negative net margin of 150,207.69%. The company had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.08 million. During the same period last year, the company posted ($0.56) earnings per share. As a group, analysts predict that Allogene Therapeutics, Inc. will post -2.32 EPS for the current year.

Allogene Therapeutics Profile

(Get Rating)

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.